## (R)-TAPI-2

**MedChemExpress** 

Cat. No.:	HY-100211A	
CAS No.:	689284-12-6	
Molecular Formula:	C <sub>19</sub> H <sub>37</sub> N <sub>5</sub> O <sub>5</sub>	
Molecular Weight:	415.53	
Target:	Others	
Pathway:	Others	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIV		
Description	(R)-TAPI-2 is the isomer of TAPI-2 (HY-100211A). TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM ), with an IC <sub>50</sub> of 20 μM for MMP <sup>[1]</sup> . TAPI-2 blocks the entry of infectious SARS-CoV <sup>[2]</sup> .	
In Vitro	The hydroxamate-based metalloprotease inhibitor TAPI-2 bounds to hmeprin with inhibition constants $IC_{50}$ 20±10 $\mu$ M for hmeprin $\beta$ subunit and 1.5±0.27 nM for hmeprin $\alpha$ subunit. Generally, hmeprin $\alpha$ is inhibited more strongly than the $\beta$ subunit <sup>[1]</sup> . Without affecting ADAM17 expression, TAPI-2 dramatically decreases the protein levels of NICD and its downstream target HES-1 in both HCP-1 and HT29 cells. Moreover, treating cells with TAPI-2 significantly decreases the C phenotype by -50% in both CRC cell lines. The dose-dependent effects of TAPI-2 on the sphere formation and protein leve of NICD and HES-1 confirm that the concentration used (20 $\mu$ M) is within the effective dose range of TAPI-2 (5-40 $\mu$ M) <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## PROTOCOL

Cell Assay <sup>[3]</sup>	TAPI-2 is dissolved in DMSO and diluted with appropriate medium before use. All experiments are performed using 20 $\mu$ TAPI-2. Cells are cultured with or without TAPI-2 for 48 hours and then seeded at 3,000 cells per well in 96-well plates. Af	
	pretreatment, increasing doses of 5-fluorouracil (5-FU) that are relevant to the recommended clinical dose (up to $2 \text{ ug/m}$ )	
	are added, with or without TAPI-2, for 72 hours. Cell viability is assessed by adding MTT substrate (0.25% in phosphate-	
	buffered saline [PBS]) in growth medium (1:5 dilution) to cells for 1 hour at 37°C. The cells are ished with PBS, and 100 µL	
	dimethyl sulfoxideis added. Optical density is measured at 570 nM, and relative MTT is presented as a percentage of control <sup>[3]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Wang R, et al. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling. Stem Cells Transl Med. 2016 Mar;5(3):331-8.

[2]. Kruse MN, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004 Mar 1;378(Pt 2):383-9.

**Product** Data Sheet

[3]. Shiori Haga, et al. TACE Antagonists Blocking ACE2 Shedding Caused by the Spike Protein of SARS-CoV Are Candidate Antiviral Compounds. Antiviral Res. 2010 Mar;85(3):551-5.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA